Injectable hydrogel system to modulate host response at bone implant interface
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsMichael Gerard Keeney, Fan Yang, Stuart Barry Goodman
Life of this patent
Estimating the term…
Abstract
A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be released by the microspheres at different times.
Claims8
A bone implant primer comprising a biodegradable hydrogel component and biomolecule release depots dispersed within the biodegradable hydrogel component, and
- wherein a first plurality of biomolecule release depots comprises biomolecules for mitigation of foreign body response including at least one of macrophage chemoattractant protein-1 or its mutant 7-ND, and
- wherein a second plurality of biomolecule release depots comprises biomolecules for aiding implant osseointegration including at least one of bone morphogenetic protein 2, bone morphogenetic protein 7, vascular endothelial growth factor, platelet-derived growth factor, or fibroblast-derived growth factor, and
- wherein the first plurality of biomolecule release depots releases biomolecules for mitigation of foreign body response for no more than 12 days, and the second plurality of biomolecule release depots releases biomolecules for implant osseointegration for at least 16 days.
An implant primer system comprising an applicator and a liquid biodegradable hydrogel component, wherein the liquid biodegradable hydrogel component becomes a solid hydrogel when dispensed by the applicator, and the applicator is adapted to dispense the liquid biodegradable hydrogel component into a bone cavity into which an implant is placed;
- and
- wherein the liquid biodegradable hydrogel component comprises biomolecule release depots dispersed within the liquid biodegradable hydrogel component;
- wherein a first plurality of biomolecule release depots comprises biomolecules for mitigation of foreign body response including at least one of macrophage chemoattractant protein-1 or its mutant 7-ND;
- and a second plurality of biomolecule release depots comprises biomolecules for aiding implant osseointegration including at least one of bone morphogenetic protein 2, bone morphogenetic protein 7, vascular endothelial growth factor, platelet-derived growth factor, or fibroblast-derived growth factor;
- and
- wherein the second plurality of biomolecule release depots continue to release the biomolecules for implant osseointegration for at least two weeks after the biodegradable hydrogel component becomes a solid hydrogel.
Dependencies are inferred from the claim text.